A review of the current use of rituximab in autoimmune diseases.

[1]  D. Keskin,et al.  Amino acid copolymer-specific IL-10-secreting regulatory T cells that ameliorate autoimmune diseases in mice , 2008, Proceedings of the National Academy of Sciences.

[2]  W. Grossman,et al.  Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias , 2008, Pediatric blood & cancer.

[3]  D. Keskin,et al.  Cytokine profiles in pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapy. , 2008, Cytokine.

[4]  D. Arnold,et al.  Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial , 2008, Annals of neurology.

[5]  D. Arnold,et al.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. , 2008, The New England journal of medicine.

[6]  Y. Shoenfeld,et al.  Intravenous Immunoglobulin Therapy Affects T Regulatory Cells by Increasing Their Suppressive Function , 2007, The Journal of Immunology.

[7]  K. Anderson,et al.  Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. , 2007, Blood.

[8]  J. Roujeau,et al.  A single cycle of rituximab for the treatment of severe pemphigus. , 2007, The New England journal of medicine.

[9]  R. Corona,et al.  Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature. , 2007, Archives of dermatology.

[10]  R. Fanin,et al.  Treatment of refractory chronic GVHD with rituximab: a GITMO study , 2007, Bone Marrow Transplantation.

[11]  A. Thomson,et al.  Tolerogenic dendritic cells and the quest for transplant tolerance , 2007, Nature Reviews Immunology.

[12]  F. Ferrara,et al.  Rituximab for warm‐type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients , 2007, European journal of haematology.

[13]  M. Franchini.  Rituximab in the treatment of adult acquired hemophilia A: a systematic review. , 2007, Critical reviews in oncology/hematology.

[14]  M. Genovese,et al.  A pilot trial of rituximab in the treatment of patients with dermatomyositis. , 2007, Archives of dermatology.

[15]  M. Sormani,et al.  Predictors of response to rituximab in patients with neuropathy and anti–myelin associated glycoprotein immunoglobulin M , 2007, Journal of the peripheral nervous system : JPNS.

[16]  Zhiliang Wang,et al.  Rapamycin-Conditioned Dendritic Cells Are Poor Stimulators of Allogeneic CD4+ T Cells, but Enrich for Antigen-Specific Foxp3+ T Regulatory Cells and Promote Organ Transplant Tolerance1 , 2007, The Journal of Immunology.

[17]  Kazuhiko Yamamoto,et al.  A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus , 2007, Modern rheumatology.

[18]  Jianping Ding,et al.  Structural Basis for Recognition of CD20 by Therapeutic Antibody Rituximab* , 2007, Journal of Biological Chemistry.

[19]  L. Kanz,et al.  Rituximab for treatment-resistant extensive Wegener`s granulomatosis—additive effects of a maintenance treatment with leflunomide , 2007, Clinical Rheumatology.

[20]  P. Foley,et al.  Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open‐label pilot study in five patients , 2007, The British journal of dermatology.

[21]  R. Looney.  Will targeting B cells be the answer for Sjögren's syndrome? , 2007, Arthritis and rheumatism.

[22]  H. Gürcan,et al.  Efficacy of Various Intravenous Immunoglobulin Therapy Protocols in Autoimmune and Chronic Inflammatory Disorders , 2007, The Annals of pharmacotherapy.

[23]  L. Hegedüs,et al.  B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study. , 2007, The Journal of clinical endocrinology and metabolism.

[24]  J. Yazdany,et al.  Six refractory lupus patients treated with rituximab: a case series. , 2007, Arthritis and rheumatism.

[25]  D. Isenberg,et al.  B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response , 2007, Annals of the rheumatic diseases.

[26]  A. Theofilopoulos,et al.  Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. , 2007, Clinical immunology.

[27]  I. Gunnarsson,et al.  Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. , 2007, Arthritis and rheumatism.

[28]  J. Freedman,et al.  Guidelines on the use of intravenous immune globulin for neurologic conditions. , 2007, Transfusion medicine reviews.

[29]  Yanping Tan,et al.  B Cell Regulation of CD4+CD25+ T Regulatory Cells and IL-10 Via B7 is Essential for Recovery From Experimental Autoimmune Encephalomyelitis1 , 2007, The Journal of Immunology.

[30]  B. Cochener,et al.  Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). , 2007, Arthritis and rheumatism.

[31]  B. Collins-Burow,et al.  Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma , 2007, Expert review of anticancer therapy.

[32]  J. Cavenagh,et al.  Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS‐13 , 2007, British journal of haematology.

[33]  M. Lindorfer,et al.  Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis , 2007, Nature Clinical Practice Rheumatology.

[34]  F. Heidel,et al.  Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia , 2007, Thrombosis and Haemostasis.

[35]  F. Dentali,et al.  Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura , 2007, Annals of Internal Medicine.

[36]  I. Rosner,et al.  Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[37]  T. Mimori,et al.  Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system , 2006, Annals of the rheumatic diseases.

[38]  M. Dougados,et al.  Consensus statement on the use of rituximab in patients with rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[39]  X. Mariette,et al.  Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren’s syndrome , 2006, Annals of the rheumatic diseases.

[40]  G. Hughes,et al.  Systemic lupus erythematosus , 2001, The Lancet.

[41]  D. Dazzi,et al.  Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. , 2007, European journal of endocrinology.

[42]  A. Aouba,et al.  Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients. , 2007, Clinical and experimental rheumatology.

[43]  R. Eisenberg.  Targeting B cells in SLE: the experience with rituximab treatment (anti-CD20). , 2006, Endocrine, Metabolic & Immune Disorders - Drug Targets.

[44]  Michael J. Ramsbottom,et al.  Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients , 2006, Journal of Neuroimmunology.

[45]  S. Amadori,et al.  Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. , 2006, Rheumatology.

[46]  L. Cavacini,et al.  Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. , 2006, The New England journal of medicine.

[47]  M. Pranzatelli,et al.  Rituximab (anti-CD20) Adjunctive Therapy for Opsoclonus-Myoclonus Syndrome , 2006, Journal of pediatric hematology/oncology.

[48]  Kenneth G. C. Smith,et al.  Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. , 2006, Arthritis and rheumatism.

[49]  L. Rostaing,et al.  Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients. , 2006, Transplantation proceedings.

[50]  A. Bryce,et al.  Response to rituximab in patients with type II cryoglobulinemia. , 2006, Clinical lymphoma & myeloma.

[51]  Stanley B. Cohen,et al.  Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. , 2006, Arthritis and rheumatism.

[52]  F. Ferrara,et al.  Rituximab therapy for chronic lymphocytic leukemia‐associated autoimmune hemolytic anemia , 2006, American journal of hematology.

[53]  J. Ritz,et al.  Rituximab for steroid-refractory chronic graft-versus-host disease. , 2006, Blood.

[54]  S. Krause,et al.  Ex Vivo-activated Human Macrophages Kill Chronic Lymphocytic Leukemia Cells in the Presence of Rituximab: Mechanism of Antibody-dependent Cellular Cytotoxicity and Impact of Human Serum , 2006, Journal of immunotherapy.

[55]  L. Quartuccio,et al.  Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. , 2006, Rheumatology.

[56]  A. Onitilo,et al.  Rituximab in the treatment of acquired factor VIII inhibitors , 2006, Thrombosis and Haemostasis.

[57]  R. González-Amaro,et al.  Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study , 2006, Arthritis research & therapy.

[58]  M. Pescovitz.  Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[59]  E. Haddad,et al.  Rituximab therapy for childhood-onset systemic lupus erythematosus. , 2006, The Journal of pediatrics.

[60]  P. Emery,et al.  The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. , 2006, Arthritis and rheumatism.

[61]  D. D'cruz.  Systemic lupus erythematosus , 2006, BMJ : British Medical Journal.

[62]  M. Battaglia,et al.  Tr1 cells: from discovery to their clinical application. , 2006, Seminars in immunology.

[63]  P. Ricciardi-Castagnoli,et al.  Induction of Peripheral T Cell Tolerance by Antigen-Presenting B Cells. II. Chronic Antigen Presentation Overrules Antigen-Presenting B Cell Activation1 , 2006, The Journal of Immunology.

[64]  G. Deuschl,et al.  High-dose rituximab and anti-MAG–associated polyneuropathy , 2006, Neurology.

[65]  H. Weiner,et al.  The mechanism of nasal tolerance in lupus prone mice is T-cell anergy induced by immature B cells that lack B7 expression. , 2006, Journal of autoimmunity.

[66]  M. Leandro,et al.  Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[67]  N. Scheinfeld.  A review of rituximab in cutaneous medicine. , 2006, Dermatology online journal.

[68]  D. Schroeder,et al.  Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. , 2006, American journal of respiratory and critical care medicine.

[69]  L. Kjeldsen,et al.  Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients , 2006, Leukemia & lymphoma.

[70]  V. Blanchette,et al.  Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[71]  R. Luqmani,et al.  Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis? , 2005, Annals of the rheumatic diseases.

[72]  D. Isenberg,et al.  Repeated B cell depletion in treatment of refractory systemic lupus erythematosus , 2005, Annals of the rheumatic diseases.

[73]  P. Aries,et al.  Lack of efficacy of rituximab in Wegener’s granulomatosis with refractory granulomatous manifestations , 2005, Annals of the rheumatic diseases.

[74]  W. Chahade,et al.  Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004). , 2006, Clinical and experimental rheumatology.

[75]  K. Beiske,et al.  Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. , 2006, Haematologica.

[76]  D. Keskin,et al.  Copolymer effects on microglia and T cells in the central nervous system of humanized mice , 2005, European journal of immunology.

[77]  D. Isenberg,et al.  B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. , 2005, Rheumatology.

[78]  R. Eisenberg.  Update on rituximab , 2005, Annals of the rheumatic diseases.

[79]  E. Kimby.  Tolerability and safety of rituximab (MabThera). , 2005, Cancer treatment reviews.

[80]  H. Hartung,et al.  Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis - results of a retrospective multicenter observational study over five years , 2005, Multiple sclerosis.

[81]  P. Woo,et al.  B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. , 2005, Arthritis and rheumatism.

[82]  P. Nathan,et al.  Corticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children: a systematic review and meta-analysis of randomized controlled trials. , 2005, The Journal of pediatrics.

[83]  G. Remuzzi,et al.  Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. , 2005, Blood.

[84]  A. Vissink,et al.  Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. , 2005, Arthritis and rheumatism.

[85]  R. Marzari,et al.  Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement‐regulatory proteins CD55 and CD59 , 2005, European journal of immunology.

[86]  P. Eriksson,et al.  Nine patients with anti‐neutrophil cytoplasmic antibody‐positive vasculitis successfully treated with rituximab , 2005, Journal of internal medicine.

[87]  P. Verginis,et al.  Tolerogenic Semimature Dendritic Cells Suppress Experimental Autoimmune Thyroiditis by Activation of Thyroglobulin-Specific CD4+CD25+ T Cells1 , 2005, The Journal of Immunology.

[88]  J. Tew,et al.  The Influence of Immune Complex-Bearing Follicular Dendritic Cells on the IgM Response, Ig Class Switching, and Production of High Affinity IgG1 , 2005, The Journal of Immunology.

[89]  E. Waubant,et al.  An open label study of the effects of rituximab in neuromyelitis optica , 2005, Neurology.

[90]  T. Plesner,et al.  Rituximab chimeric anti‐CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura , 2005, American journal of hematology.

[91]  D. Isenberg,et al.  Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against rituximab. , 2005, Rheumatology.

[92]  P. Sfikakis,et al.  Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. , 2005, Arthritis and rheumatism.

[93]  J. Bussel,et al.  Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. , 2005, The Journal of pediatrics.

[94]  T. Levine.  Rituximab in the treatment of dermatomyositis: an open-label pilot study. , 2005, Arthritis and rheumatism.

[95]  K. Fujii,et al.  Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. , 2005, Rheumatology.

[96]  M. Dougados,et al.  Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases , 2004, Annals of the rheumatic diseases.

[97]  A. Shad,et al.  Treatment of Immune Thrombocytopenic Purpura in Children , 2005, Paediatric drugs.

[98]  J. Stone,et al.  Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. , 2005, Arthritis and rheumatism.

[99]  M. Sneller.  Rituximab and Wegener's granulomatosis: are B cells a target in vasculitis treatment? , 2005, Arthritis and rheumatism.

[100]  A. Mehta,et al.  Rituximab in the treatment of refractory autoimmune cytopenias in adults. , 2005, Haematologica.

[101]  J. Cook,et al.  Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura , 2005, Annals of Hematology.

[102]  Taku Sato,et al.  Aberrant B1 cell migration into the thymus results in activation of CD4 T cells through its potent antigen‐presenting activity in the development of murine lupus , 2004, European journal of immunology.

[103]  G. Mazzucco,et al.  Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[104]  Peter A Calabresi,et al.  Diagnosis and management of multiple sclerosis. , 2004, American family physician.

[105]  A. Cappione,et al.  Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. , 2004, Arthritis and rheumatism.

[106]  J. G. van den Tweel,et al.  Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. , 2004, Blood.

[107]  A. Achiron,et al.  Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. , 2004, Archives of neurology.

[108]  D. Keskin,et al.  Amelioration of proteolipid protein 139-151-induced encephalomyelitis in SJL mice by modified amino acid copolymers and their mechanisms. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[109]  I. Sanz,et al.  B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. , 2004, Arthritis and rheumatism.

[110]  M. Sailer,et al.  Increased blood plasma concentrations of TGF-β isoforms after treatment with intravenous immunoglobulins (IVIG) in patients with multiple sclerosis , 2004, Journal of Neuroimmunology.

[111]  P. Emery,et al.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. , 2004, The New England journal of medicine.

[112]  S. Amadori,et al.  Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. , 2004, Blood.

[113]  N. Nguyen,et al.  Rituximab in patients with refractory thrombotic thrombocytopenic purpura , 2004, Journal of thrombosis and haemostasis : JTH.

[114]  F. Shammas,et al.  Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. , 2004, Blood.

[115]  D. Nemazee,et al.  B Cell Selection Defects Underlie the Development of Diabetogenic APCs in Nonobese Diabetic Mice1 , 2004, The Journal of Immunology.

[116]  J. Leonard,et al.  The efficacy and safety of B‐cell depletion with anti‐CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura , 2004, British journal of haematology.

[117]  A. Thomson,et al.  Dendritic cells: emerging pharmacological targets of immunosuppressive drugs , 2004, Nature Reviews Immunology.

[118]  A. Newland,et al.  Idiopathic Thrombocytopenic Purpura in Adults , 2003, Journal of pediatric hematology/oncology.

[119]  J. Penner,et al.  Refractory autoimmune thrombocytopenic purpura: Responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab) , 2003, American journal of hematology.

[120]  T. Shanafelt,et al.  Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. , 2003, Mayo Clinic proceedings.

[121]  T. Shaw,et al.  B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience , 2003, Annals of the rheumatic diseases.

[122]  R. Hohlfeld,et al.  Polymyositis and dermatomyositis , 2003, The Lancet.

[123]  M. Becker,et al.  Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[124]  K. Bhol,et al.  Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris. , 2003, European journal of dermatology : EJD.

[125]  U. Khanderia,et al.  Diagnosis and Treatment of Graves Disease , 2003, The Annals of pharmacotherapy.

[126]  G. Remuzzi,et al.  Rituximab in idiopathic membranous nephropathy: a one-year prospective study. , 2003, Journal of the American Society of Nephrology : JASN.

[127]  R. Fanin,et al.  Efficacy and safety of rituximab in type II mixed cryoglobulinemia. , 2003, Blood.

[128]  S. Perrotta,et al.  Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. , 2003, Blood.

[129]  Felicia A Tucci,et al.  Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. , 2003, Blood.

[130]  G. Deuschl,et al.  Rituximab in the treatment of polyneuropathy associated with anti‐MAG antibodies , 2003, Muscle & nerve.

[131]  Timothy A. Miller,et al.  Treatment of IgM antibody associated polyneuropathies using rituximab , 2003, Journal of neurology, neurosurgery, and psychiatry.

[132]  A. Rudensky,et al.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.

[133]  I. Sanz,et al.  The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus , 2003 .

[134]  S. Kaveri,et al.  Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. , 2003, Blood.

[135]  T. Nomura,et al.  Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2002 .

[136]  R. Fanin,et al.  B-cell compartment as the selective target for the treatment of immune thrombocytopenias. , 2003, Haematologica.

[137]  A. Ahmed,et al.  Influence of IVIg therapy on autoantibody titers to desmoglein 1 in patients with pemphigus foliaceus. , 2002, Clinical immunology.

[138]  D. Isenberg,et al.  An open study of B lymphocyte depletion in systemic lupus erythematosus. , 2002, Arthritis and rheumatism.

[139]  N Gupta,et al.  Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia , 2002, Leukemia.

[140]  D. Keskin,et al.  Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase , 2002, Science.

[141]  R. Wassmuth,et al.  Fcγ receptor IIa, IIIa, and IIIb polymorphisms in German patients with systemic lupus erythematosus: association with clinical symptoms , 2002, Annals of the rheumatic diseases.

[142]  U. Germing,et al.  Treatment of relapsed idiopathic thrombocytopenic purpura with the anti‐CD20 monoclonal antibody rituximab: a pilot study , 2002, European journal of haematology.

[143]  A. Tefferi,et al.  Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses , 2002, Annals of Hematology.

[144]  R. Jonsson,et al.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group , 2002, Annals of the rheumatic diseases.

[145]  S. Amadori,et al.  Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. , 2002, Blood.

[146]  C. Geisler,et al.  The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. , 2002, Blood.

[147]  D. Keskin,et al.  Functional expression of indoleamine 2,3-dioxygenase by murine CD8α+ dendritic cells , 2002 .

[148]  Yuni Fang,et al.  Binding to CD20 by Anti-B1 Antibody or F(ab')2 is sufficient for induction of apoptosis in B-cell lines , 2002, Cancer Immunology, Immunotherapy.

[149]  A. Fischer,et al.  Treatment of childhood autoimmune haemolytic anaemia with rituximab , 2001, The Lancet.

[150]  E. Løkkevik,et al.  Favourable response to therapy with the anti‐CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease , 2001, British journal of haematology.

[151]  U. Jäger,et al.  CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells , 2001, Leukemia.

[152]  S. Amadori,et al.  Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. , 2001, Blood.

[153]  S. Kumari,et al.  Pemphigus vulgaris: the role of IL-1 and IL-1 receptor antagonist in pathogenesis and effects of intravenous immunoglobulin on their production. , 2001, Clinical immunology.

[154]  N. Mitsiades,et al.  Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies , 2001, Journal of immunotherapy.

[155]  J. Ravetch,et al.  Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. , 2001, Science.

[156]  G. Appel,et al.  Advances in the treatment of lupus nephritis. , 2001, Annual review of medicine.

[157]  R. Hardy,et al.  B cell development pathways. , 2001, Annual review of immunology.

[158]  A. Grillo‐López.  Rituximab: an insider's historical perspective. , 2000, Seminars in oncology.

[159]  J. Bussel.  Overview of idiopathic thrombocytopenic purpura: new approach to refractory patients. , 2000, Seminars in oncology.

[160]  J. Gutheil,et al.  A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. , 2000, Seminars in oncology.

[161]  S. Bernasconi,et al.  Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. , 2000, Blood.

[162]  Meri,et al.  Rituximab (Anti‐CD20) Therapy of B‐Cell Lymphomas: Direct Complement Killing is Superior to Cellular Effector Mechanisms , 2000, Scandinavian journal of immunology.

[163]  C. Marcocci,et al.  Management of Graves' ophthalmopathy: reality and perspectives. , 2000, Endocrine reviews.

[164]  K. Sullivan,et al.  Pathophysiology and treatment of graft-versus-host disease. , 1999, Hematology/oncology clinics of North America.

[165]  A. Naji,et al.  I-Ag7-mediated antigen presentation by B lymphocytes is critical in overcoming a checkpoint in T cell tolerance to islet beta cells of nonobese diabetic mice. , 1999, Journal of immunology.

[166]  A. Pestronk,et al.  IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab , 1999, Neurology.

[167]  A. Enk,et al.  Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells. , 1999, Blood.

[168]  M. Toda,et al.  Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. , 1998, International immunology.

[169]  J. Moake,et al.  Thrombotic thrombocytopenic purpura: understanding a disease no longer rare. , 1998, The American journal of the medical sciences.

[170]  C. Helmick,et al.  Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. , 1998, Arthritis and rheumatism.

[171]  A. Enk,et al.  Induction of tolerance by IL-10-treated dendritic cells. , 1997, Journal of immunology.

[172]  U. Dafni,et al.  Prevalence of Sjögren’s syndrome in a closed rural community , 1997, Annals of the rheumatic diseases.

[173]  M. Crow,et al.  Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. , 1996, The Journal of clinical investigation.

[174]  R. Ramsey‐Goldman,et al.  Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. , 1996, The Journal of clinical investigation.

[175]  G. F. Burton,et al.  Follicular dendritic cells and the maintenance of IgE responses , 1995, European journal of immunology.

[176]  J. Cavaillon,et al.  Selective induction of interleukin‐1 receptor antagonist and interleukin‐8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin) , 1995, European journal of immunology.

[177]  M. Cooke,et al.  Self-tolerance checkpoints in B lymphocyte development. , 1995, Advances in immunology.

[178]  F. Finkelman,et al.  In vivo activation of naive T cells by antigen-presenting B cells. , 1994, Journal of immunology.

[179]  R J Falk,et al.  Nomenclature of systemic vasculitides. Proposal of an international consensus conference. , 1994, Arthritis and rheumatism.

[180]  P. Chinn,et al.  Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. , 1994, Blood.

[181]  J. Dambrosia,et al.  A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. , 1993, The New England journal of medicine.

[182]  U. Andersson,et al.  Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. , 1993, Immunology.

[183]  M. Pranzatelli.  The neurobiology of the opsoclonus-myoclonus syndrome. , 1992, Clinical neuropharmacology.

[184]  F. Epstein,et al.  Rheumatoid arthritis. Pathophysiology and implications for therapy. , 1990, The New England journal of medicine.

[185]  L. Nadler,et al.  Characterization of a human B lymphocyte-specific antigen. , 1980, Journal of immunology.

[186]  M. Meltzer,et al.  Cryoglobulinemia--a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. , 1966, The American journal of medicine.

[187]  E W WALTON,et al.  Giant-cell Granuloma of the Respiratory Tract (Wegener's Granulomatosis) , 1958, British medical journal.